BOULDER, Colo. & BEVERLY, Mass.--(BUSINESS WIRE)--Enzymatics today launches a new targeted sequencing assay for detecting and identifying fusions of 26 genes associated with sarcoma. Using Enzymatics’ proprietary Anchored Multiplex PCR™-based enrichment, fusions of all genes in the panel can be identified in a single sequencing run, without prior knowledge of fusion partners or breakpoints. The assay will join the ALK, RET, ROS1 v2 panel and the Heme panel as the newest addition to the Archer™ FusionPlex™ product line.
Help employers find you! Check out all the jobs and post your resume.
